MedTrace Logo

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

NCT06702826 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-11-25

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).

The main questions it aims to answer are:

* Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results?
* Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC：
* Receive Cadonilimab combined with SRT for brain lesions.
* Visit the hospital regularly once every 12 weeks for checkups and tests

Conditions

  • Non Small Cell Lung Cancer
  • Brain Metastases
  • Stereotactic Radiation
  • Immunotherapy

Interventions

DRUG

Cadonilimab combined with SRS

Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone

Sponsors & Collaborators

  • Rongrong Zhou

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2027-11-01
Completion
2027-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06702826 on ClinicalTrials.gov